Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IYE vs XBI: how they differ
IYE and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares U.S. Energy ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, IYE and XBI hold 0% of their money in the same securities at the same weight.
| Only in IYE | Only in XBI |
|---|---|
| EXXON MOBIL CORPORATION 21.74% | Apogee Therapeutics Inc 1.49% |
| CHEVRON CORPORATION 15.41% | Moderna Inc 1.41% |
| CONOCOPHILLIPS 6.51% | Twist Bioscience Corp 1.41% |
| THE WILLIAMS COMPANIES, INC. 4.38% | Oruka Therapeutics Inc 1.38% |
| SLB N.V. 3.95% | Kymera Therapeutics Inc 1.36% |
| EOG RESOURCES, INC. 3.56% | Viking Therapeutics Inc 1.31% |
| VALERO ENERGY CORPORATION 3.54% | Praxis Precision Medicines Inc 1.29% |
| MARATHON PETROLEUM CORPORATION 3.44% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| IYE iShares U.S. Energy ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | U.S. Energy | SPDR S&P Biotech |
| Total return, 1 year | +48.8% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +31.3 pts | +46.5 pts |
| Expense ratio | 0.37% | 0.35% |
| Already in the S&P 500 | 89.0% | 8.5% |
| Holdings | 38 | 150 |
IYE in plain words
IYE is an index equity fund tracking the U.S. Energy. Over the year to Sep 11, 2026 it returned +48.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.37% a year. By its holdings filed for Apr 30, 2026, 89% of the fund by weight is stocks the S&P 500 also holds, across 38 positions, with the top ten at 69.0%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IYE or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, IYE returned +48.8% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IYE or XBI?
- IYE charges 0.37% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do IYE and XBI overlap with the S&P 500?
- By their latest filed holdings, 89% of IYE and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IYE against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/IYE-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources